Dynamic Contrast-Enhanced Imaging as a Prognostic Tool in Early Diagnosis of Prostate Cancer: Correlation with PSA and Clinical Stage

Table 2

Comparison of the 62 patients with peripheral and transitional zone prostate cancer (46 versus 16): age, tumor size, and DWI- and DCE-derived tumor parameters.

	Total mean ± SD	Peripheral mean ± SD	Transitional mean ± SD	value
Age (years)	70 ± 5	70 ± 5	70 ± 4	0.974
PSA (ng/mL)	9.5 ± 3.7	9.7 ± 3.9	9.1 ± 3.3	0.552
Area of tumor (cm^2)	0.74 ± 0.47	0.68 ± 0.41	0.93 ± 0.59	0.037
ADC (×10^−3 mm^2/s)	0.87 ± 0.16	0.89 ± 0.17	0.82 ± 0.13	0.259
K^trans (min^−1)	0.15 ± 0.05	0.15 ± 0.05	0.14 ± 0.06	0.743
Kep (min^−1)	0.57 ± 0.22	0.59 ± 0.21	0.49 ± 0.24	0.048
Ve	0.28 ± 0.08	0.27 ± 0.08	0.32 ± 0.07	0.026
iAUC (mmoL/L/min)	16.70 ± 5.69	17.26 ± 5.51	15.86 ± 6.21	0.626

PSA, prostate-specific antigen; ADC, apparent diffusion coefficient; K^trans, volume transfer constant; K_ep, reflux constant; Ve, extravascular extracellular leakage volume fraction; iAUC, initial area under curve; n, number of tumors.